Frontiers in Oncology (Oct 2022)

Immune checkpoint inhibitors in cervical cancer: Current status and research progress

  • Yunkai Xie,
  • Weimin Kong,
  • Xiaoling Zhao,
  • He Zhang,
  • Dan Luo,
  • Shuning Chen

DOI
https://doi.org/10.3389/fonc.2022.984896
Journal volume & issue
Vol. 12

Abstract

Read online

Cervical cancer is the second most common gynecological malignant tumor endangering the health of women worldwide. Despite advances in the therapeutic strategies available to treat cervical cancer, the long-term prognosis of patients with recurrent and metastatic cervical cancer remains unsatisfactory. In recent years, immune checkpoint inhibitors (ICIs) have shown encouraging efficacy in the treatment of cervical cancer. ICIs have been approved for use in both first- and second-line cervical cancer therapies. This review summarizes the current knowledge of ICIs and the application of ICIs in clinical trials for the treatment of cervical cancer.

Keywords